Evidence map›Paper›PMID 23793035›Full record

ArticleAnnals of oncology : official journal of the European Society for Medical Oncology2013

Obesity, diabetes, and survival outcomes in a large cohort of early-stage breast cancer patients.

S Jiralerspong, E S Kim, W Dong, L Feng, G N Hortobagyi, S H Giordano

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Annals of oncology : official journal of the European Society for Medical Oncology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 98 papers, 9 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
98citing papers in PubMed, 9 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

98 citing papers in PubMed, 9 syntheses or guidelines pooled it.

  1. The effect of BMI on survival outcome of breast cancer patients: a systematic review and meta-analysis.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2025
    Pooled it
  2. Pooled it
  3. Benefits of weight loss programs for breast cancer survivors: a systematic reviews and meta-analysis of randomized controlled trials.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2022
    Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Trial
  11. Trial
  12. Trial
  13. Body Mass Index at Diagnosis and Breast Cancer Survival Prognosis in Clinical Trial Populations from NRG Oncology/NSABP B-30, B-31, B-34, and B-38.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2016
    Trial
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article

38 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

S JiralerspongLester and Sue Smith Breast Center, Department of Medicine, Dan L. Duncan Cancer Center, Baylor College of Medicine, Houston; Department of Breast Medical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston. Electronic address: jiralers@bcm.edu.
E S KimDepartment of Breast Medical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston; James P. Wilmot Cancer Center, Department of Medicine, University of Rochester, Rochester.
W DongDepartment of Biostatistics, The University of Texas M. D. Anderson Cancer Center, Houston, USA.
L FengDepartment of Biostatistics, The University of Texas M. D. Anderson Cancer Center, Houston, USA.
G N HortobagyiDepartment of Breast Medical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston.
S H GiordanoDepartment of Breast Medical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston.

Funding

Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Fabien Delerue · 1985 to 2026
$290.8M
Adherence Among Older Women with Breast CancerK07CA109064 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI GIORDANO, SHARON HERMES · 2004 to 2009
$729k
NCI NIH HHS K07CA109064NCI NIH HHS P30 CA016672
6 · The paper itself

Abstract

backgroundTo determine the relationship between obesity, diabetes, and survival in a large cohort of breast cancer patients receiving modern chemotherapy and endocrine therapy. PATIENTS AND

methodsWe identified 6342 patients with stage I-III breast cancer treated between 1996 and 2005. Patients were evaluated according to body mass index (BMI) category and diabetes status.

resultsIn a multivariate model adjusted for body mass index, diabetes, medical comorbidities, patient- and tumor-related variables, and adjuvant therapies, relative to the normal weight, hazard ratios (HRs) for recurrence-free survival (RFS), overall survival (OS), and breast cancer-specific survival (BCSS) for the overweight were 1.18 [95% confidence interval (CI) 1.02-1.36], 1.20 (95% CI 1.00-1.42), and 1.21 (95% CI 0.98-1.48), respectively. HRs for RFS, OS, and BCSS for the obese were 1.13 (95% CI 0.98-1.31), 1.24 (95% CI 1.04-1.48), and 1.23 (95% CI 1.00-1.52), respectively. Subset analyses showed these differences were significant for the ER-positive, but not ER-negative or HER2-positive, groups. Relative to nondiabetics, HRs for diabetics for RFS, OS, and BCSS were 1.21 (95% CI 0.98-1.49), 1.39 (95% CI 1.10-1.77), and 1.04 (95% CI 0.75-1.45), respectively.

conclusionsIn patients receiving modern adjuvant therapies, obesity has a negative impact on RFS, OS, and BCSS; and diabetes has a negative impact on RFS and OS. Control of both may be important to improving survival in obese and diabetic breast cancer patients.

Indexed as

AnthracyclinesAntineoplastic Agents, HormonalAromatase InhibitorsBody CompositionBody Mass IndexBreast NeoplasmsBridged-Ring CompoundsCohort StudiesDiabetes MellitusDisease-Free SurvivalErb-b2 Receptor Tyrosine KinasesFemaleHumansMiddle AgedObesityPaclitaxelAnthracyclinesAntineoplastic Agents, HormonalAromatase InhibitorsBridged-Ring CompoundsERBB2 protein, humanErb-b2 Receptor Tyrosine KinasesPaclitaxelReceptors, EstrogenTamoxifentaxaneTaxoidsbody mass indexbreast cancerdiabetesobesityprognosissurvival outcomes

Identifiers

PMID23793035
PMCPMC3784334

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.